Structure Therapeutics (GPCR) News Today $20.46 -0.59 (-2.78%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Consensus Rating of "Buy" from AnalystsStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are presently covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price targetMarch 25 at 4:40 AM | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Shares Down 6.1% - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.1% - Should You Sell?March 21, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading 6% Higher - What's Next?Structure Therapeutics (NASDAQ:GPCR) Trading Up 6% - Should You Buy?March 20, 2025 | marketbeat.comPlatinum Investment Management Ltd. Has $2.03 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)Platinum Investment Management Ltd. raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 30.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 74,900 shares of the company's stock after buying an additional 17,670March 20, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.1% - Time to Sell?Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.1% - Here's What HappenedMarch 14, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?March 13, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low - Time to Sell?Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year Low - Here's WhyMarch 12, 2025 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by Candriam S.C.A.Candriam S.C.A. lifted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 59.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 215,421 shares of the company's stock after acquiring an additional 80,42March 9, 2025 | marketbeat.comStructure Therapeutics (GPCR) Projected to Post Quarterly Earnings on FridayStructure Therapeutics (NASDAQ:GPCR) will be releasing earnings before the market opens on Friday, March 14, Financial Modeling Prep reports.March 7, 2025 | marketbeat.comAnalysts Set Expectations for GPCR Q4 EarningsStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Leerink Partnrs issued their Q4 2025 earnings per share estimates for shares of Structure Therapeutics in a research note issued to investors on Monday, March 3rd. Leerink Partnrs analyst D. Risinger expects that the company will earn $2.5March 6, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for GPCR Q1 Earnings?Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Structure Therapeutics in a research report issued to clients and investors on Monday, March 3rd. Leerink Partnrs analyst D. Risinger forecasts that the comMarch 4, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Outperform RecommendationMarch 1, 2025 | msn.comStructure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William BlairWilliam Blair began coverage on shares of Structure Therapeutics in a research note on Friday. They issued an "outperform" rating on the stock.March 1, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSStructure Therapeutics (NASDAQ:GPCR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01.February 28, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Shares Up 8% on Earnings BeatStructure Therapeutics (NASDAQ:GPCR) Trading Up 8% on Earnings BeatFebruary 28, 2025 | marketbeat.comRSI Alert: Structure Therapeutics (GPCR) Now OversoldFebruary 28, 2025 | nasdaq.comStifel Nicolaus Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)February 28, 2025 | markets.businessinsider.comStructure Therapeutics price target lowered to $87 from $91 at Citizens JMPFebruary 28, 2025 | markets.businessinsider.comStructure Therapeutics Inc. (NASDAQ:GPCR) Given Average Rating of "Buy" by AnalystsShares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have earned an average rating of "Buy" from the seven ratings firms that are covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target price amoFebruary 28, 2025 | marketbeat.comStructure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent HighlightsFebruary 27, 2025 | tmcnet.comStructure Therapeutics initiated with an Outperform at William BlairFebruary 27, 2025 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)February 27, 2025 | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Trading Down 6.4% - Should You Sell?Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4% - Time to Sell?February 27, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Sets New 12-Month Low - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low - Here's What HappenedFebruary 24, 2025 | marketbeat.comHandelsbanken Fonder AB Takes $4.48 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Handelsbanken Fonder AB acquired a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 165,000 shares of the company's stock, valuedFebruary 24, 2025 | marketbeat.comPrincipal Financial Group Inc. Buys 245,775 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Principal Financial Group Inc. raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 791,134 shares of the coFebruary 24, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading Up 6.2% - Should You Buy?Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 6.2% - Still a Buy?February 22, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low - Here's What HappenedStructure Therapeutics (NASDAQ:GPCR) Sets New 1-Year Low - What's Next?February 19, 2025 | marketbeat.comShort Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Declines By 20.4%Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 7,850,000 shares, a decline of 20.4% from the January 15th total of 9,860,000 shares. Based on an average trading volume of 885,400 shares, the short-interest ratio is presently 8.9 days. Approximately 14.5% of the company's stock are short sold.February 16, 2025 | marketbeat.comWhy Structure Therapeutics Stock Was Stumbling This WeekFebruary 14, 2025 | fool.comabrdn plc Has $4.65 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)abrdn plc decreased its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 21.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 171,388 shares of the company's stock after selling 45,695 shares during the quaFebruary 10, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.7% - Should You Sell?Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.7% - What's Next?February 7, 2025 | marketbeat.com8,949 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Spire Wealth ManagementSpire Wealth Management purchased a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,949 shares of the company's stoFebruary 7, 2025 | marketbeat.comSA Asks: What's the most attractive weight-loss stock right now?February 5, 2025 | msn.comStructure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Rating of "Buy" by BrokeragesStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price target among brFebruary 3, 2025 | marketbeat.comCCG Wealth Management LLC Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR)CCG Wealth Management LLC acquired a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 150,000 shares of the company's stock, valuedFebruary 3, 2025 | marketbeat.comShort Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8%Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 10,750,000 shares, an increase of 5.8% from the December 31st total of 10,160,000 shares. Currently, 19.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 824,600 shares, the days-to-cover ratio is currently 13.0 days.February 3, 2025 | marketbeat.comStructure Therapeutics to Participate in Multiple Upcoming Healthcare Investor ConferencesJanuary 30, 2025 | globenewswire.comStructure Therapeutics (NASDAQ:GPCR) Trading 8.3% Higher - Should You Buy?Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 8.3% - Time to Buy?January 29, 2025 | marketbeat.comWe're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn RateJanuary 24, 2025 | finance.yahoo.comJPMorgan Chase & Co. Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR)JPMorgan Chase & Co. raised its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 302.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,936 shares of the company's stock afterJanuary 24, 2025 | marketbeat.comExicure Buys GPCR USA From GPCR Therapeutics, Signs L&C Deal; Stock ClimbsJanuary 23, 2025 | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low - Should You Sell?Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low - What's Next?January 10, 2025 | marketbeat.comStifel Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy RecommendationJanuary 8, 2025 | msn.comStifel Nicolaus Initiates Coverage on Structure Therapeutics (NASDAQ:GPCR)Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday. They set a "buy" rating and a $50.00 price target for the company.January 8, 2025 | marketbeat.comInnovative Oral Treatments for Obesity: Structure Therapeutics Earns Buy Rating with Promising Pipeline and Strategic VisionJanuary 8, 2025 | markets.businessinsider.comStructure Therapeutics initiated with a Buy at StifelJanuary 8, 2025 | markets.businessinsider.comStructure Therapeutics: Competitive Data Is EmergingJanuary 3, 2025 | seekingalpha.comStructure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year Low - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Hits New 1-Year Low - What's Next?December 31, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5% - Here's WhyStructure Therapeutics (NASDAQ:GPCR) Trading Down 5.5% - Here's What HappenedDecember 30, 2024 | marketbeat.com Remove Ads Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address GPCR Media Mentions By Week GPCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GPCR News Sentiment▼0.670.63▲Average Medical News Sentiment GPCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GPCR Articles This Week▼44▲GPCR Articles Average Week Remove Ads Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTC Therapeutics News ADMA Biologics News Zai Lab News Avidity Biosciences News Organon & Co. News Arcellx News SpringWorks Therapeutics News Ultragenyx Pharmaceutical News Akero Therapeutics News Alvotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GPCR) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GPCR Stock Free GPCR Stock Alerts